Blindness arising from retinal or macular degeneration results in significant social, health and economic burden. While approved treatments exist for neovascular (') age-related macular degeneration, new therapeutic targets/interventions are needed for the more prevalent atrophic (') form of age-related macular degeneration. Similarly, in inherited retinal diseases, most patients have no access to an effective treatment.
View Article and Find Full Text PDF